Filtered By:
Drug: Stelara
This page shows you your search results in order of date.
Order by Relevance | Date
Total 10 results found since Jan 2013.
Johnson & Johnson Reports Q4 and Full-Year 2022 Results
NEW BRUNSWICK, N.J. – January 24, 2023 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value...
Source: Johnson and Johnson - January 24, 2023 Category: Pharmaceuticals Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?
CONCLUSIONS: Our retrospective study suggests that in first-line TNFi failure TAK patients both switch and swap strategies can be considered suitable approaches.PMID:33666154
Source: Clinical and Experimental Rheumatology - March 5, 2021 Category: Rheumatology Authors: Corrado Campochiaro Alessandro Tomelleri Elena Galli Emanuele Cocchiara Silvia Sartorelli Francesco Muratore Clara Malattia Roberta Caorsi Maria Grazia Catanoso Elena Baldissera Angelo Ravelli Carlo Salvarani Lorenzo Dagna Source Type: research
Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Stroke under treatment with ustekinumab for psoriatic arthritis.
Authors: Aboudiab M, Andréjak M, Husein T, Goëb V
PMID: 30638925 [PubMed - as supplied by publisher]
Source: Revue Neurologique - January 16, 2019 Category: Neurology Tags: Rev Neurol (Paris) Source Type: research
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
CONCLUSION: Based on data accumulated to date in PSOLAR, treatment with biologics did not have an impact on the risk of MACE in patients with moderate-to-severe psoriasis. <p><em>J Drugs Dermatol. 2017;16 (10):1002-1013.</em></p>.
PMID: 29036254 [PubMed - in process]
Source: Journal of Drugs in Dermatology - October 18, 2017 Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Response to: 'Biologic agents for giant cell arteritis: treat to target by Moiseev et al
We thank Moiseev et al for their interest in our study of ustekinumab in giant cell arteritis (GCA).1 2 Our pilot study reported promising initial results from the use of ustekinumab in GCA.1 GCA is a potentially devastating disease with cranial ischaemic complications such as blindness and stroke occurring in 20%–25% of patients.3 While corticosteroids are effective in reducing the risk of cranial ischaemic complications, they do not fully extinguish the vascular inflammation in patients with GCA4–6 with consequent risk of disease relapse and longer-term consequences such as aortic aneurysms.7 8 Furthermore, c...
Source: Annals of the Rheumatic Diseases - August 9, 2016 Category: Rheumatology Authors: Conway, R., Molloy, E. S. Tags: Electronic pages Source Type: research
Cardiovascular outcomes and systemic anti‐inflammatory drugs in patients with severe psoriasis: 5‐year follow‐up of a Danish nationwide cohort
ConclusionSystemic anti‐inflammatory treatment with methotrexate was associated with significantly lower rates of cardiovascular events during long‐term follow‐up compared to patients treated with other antipsoriatic therapies. The treatment strategy in patients with severe psoriasis may have an impact on cardiovascular outcomes and randomized trials to evaluate the cardiovascular safety and efficacy of systemic antipsoriatic therapies are called for.
Source: Journal of the European Academy of Dermatology and Venereology - October 10, 2014 Category: Dermatology Authors: O. Ahlehoff, L. Skov, G. Gislason, R. Gniadecki, L. Iversen, L.E. Bryld, S. Lasthein, J. Lindhardsen, S.L. Kristensen, C. Torp‐Pedersen, P.R. Hansen Tags: Original Article Source Type: research
